These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12807692)

  • 1. An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
    Nicodemo AC
    Braz J Infect Dis; 2003 Feb; 7(1):62-8. PubMed ID: 12807692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
    Nicholson SC; Wilson WR; Naughton BJ; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):117-25. PubMed ID: 12376041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
    Franca SA; Carvalho CR
    Braz J Infect Dis; 2002 Aug; 6(4):157-63. PubMed ID: 12204182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
    Mandell LA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042
    [No Abstract]   [Full Text] [Related]  

  • 7. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
    Jones RN; Andes DR; Mandell LA; Gothelf S; Ehrhardt AF; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):93-100. PubMed ID: 12376038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H; Magyar P; Muir JF; Loos U; Kleutgens K;
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
    Sher LD; Poole MD; Von Seggern K; Wikler MA; Nicholson SC; Pankey GA
    Otolaryngol Head Neck Surg; 2002 Sep; 127(3):182-9. PubMed ID: 12297808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
    Nicholson SC; High KP; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
    Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
    Mandell LA
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):65-7. PubMed ID: 12376034
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
    Okimoto N; Kibayashi T; Mimura K; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N; Ohba H
    J Infect Chemother; 2005 Dec; 11(6):274-7. PubMed ID: 16369733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.
    Trémolières F; de Kock F; Pluck N; Daniel R
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):447-53. PubMed ID: 9758291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
    Medeiros EA
    Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide, multicenter survey on the efficacy and safety of piperacillin for adult community-acquired pneumonia in Japan.
    Yamamoto Y; Watanabe A; Goto H; Matsushima T; Abe S; Aoki N; Shimokata K; Mikasa K; Niki Y; Kohno S
    J Infect Chemother; 2012 Aug; 18(4):544-51. PubMed ID: 22618270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.